Immunis, Inc.
↗Irvine, California, USA
Immunis is a private biotechnology company developing a novel, multi-potent secretome product derived from stem cells to address age-related immune decline and muscle wasting. The company's platform focuses on the 'secretome'—the collection of proteins and factors secreted by cells—rather than the cells themselves, aiming to provide a more scalable and safer regenerative therapy.
Their lead candidate, IMM01-STEM, is designed to reverse sarcopenia (muscle loss) and improve immune function in the elderly. The company operates out of Irvine, California, and leverages proprietary manufacturing processes to produce high-concentration secretome formulations for clinical use.
CLASSIFICATION
Company Type:Biotech
Therapeutic Areas:
Industry:Biotechnology
Sub-Industry:Regenerative Medicine / Longevity
SIZE & FINANCIALS
Employees:1-50
Revenue:Pre-revenue
Founded:2021
Ownership:private
Status:operating
FUNDING
Stage:Seed
Total Raised:$10M
Investors:Remus Capital, Various Private Investors
PIPELINE
Stage:Phase 1/2
Lead Drug Stage:Phase 1/2a
Modalities:Secretome, Stem cell-derived factors, Biologics
Active Trials:1
Trial Phases:Phase 1: 1 | Phase 2: 1
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:University of California, Irvine (Research collaboration)
COMPETITION
Position:Emerging
Competitors:BioAge Labs, Unity Biotechnology, Rejuvenate Bio, Rubedo Life Sciences
LEADERSHIP
Key Executives:
Hans Keirstead, Ph.D. - Chairman & CEO
Mihaela Nistor, Ph.D. - COO
Scientific Founders:Hans Keirstead
Board Members:Hans Keirstead, Kanav Kariya
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Immunis, Inc.. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.